An economic evaluation of the effectiveness of telemedicine in hematooncology.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2023
2023
Historique:
received:
11
04
2023
accepted:
22
08
2023
medline:
16
11
2023
pubmed:
14
11
2023
entrez:
14
11
2023
Statut:
epublish
Résumé
The article examines the effectiveness of remote monitoring and the evaluation of facts about patients with hematologic malignancies using telemedicine based on SMART technologies. The project was carried out in the Department of Haematooncology of the University Hospital Ostrava. Its objective was to test the efficacy of telemedicine in the treatment of patients with blood cancer. The cost-benefit analysis method was used to evaluate effectiveness, which also confirmed the feasibility of using this method to evaluate the costs and benefits of implementing specific medical projects. The conducted analysis demonstrated the effectiveness of using telemedicine procedures in the treatment of these patients, both in terms of quantifiable and non-quantifiable impacts on the Czech Republic's health system. This was mainly due to a large shortening of the length of the hospitalisation period for patients with problems whose deterioration was discovered by remote monitoring and their treatment could begin promptly. The shortening of the hospitalization period was achieved by around 40%. As a result, the complexity of treatment has been greatly reduced, benefiting both the hospital and, most importantly, the patient. With this prevention, the patient's chances of dying are reduced, as he or she is less likely to develop severe septic diseases. The total average financial savings of the Czech Republic's entire health care system for a patient who does not become septic due to a delayed response to deteriorating health only in hospitalisation, treatment, and medications is approximately USD 2,800.
Identifiants
pubmed: 37963144
doi: 10.1371/journal.pone.0291143
pii: PONE-D-23-07270
pmc: PMC10645329
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0291143Informations de copyright
Copyright: © 2023 Lebiedzik et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Eur Heart J. 2016 May 07;37(18):1428-38
pubmed: 26873093
Ann Oncol. 2016 Sep;27(suppl 5):v111-v118
pubmed: 27664247
Emerg Med Clin North Am. 2014 Aug;32(3):549-61
pubmed: 25060249
Health Aff (Millwood). 2014 Feb;33(2):194-9
pubmed: 24493760
Antimicrob Agents Chemother. 2014 Jul;58(7):3799-803
pubmed: 24752269
Cancer Manag Res. 2022 May 04;14:1655-1661
pubmed: 35547597
JCO Clin Cancer Inform. 2021 Oct;5:1096-1105
pubmed: 34735265
Support Care Cancer. 2015 Sep;23(9):2799-804
pubmed: 25663578